Aerie Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AERI)

$59.30 1.40 (2.42 %)
(As of 01/21/2018 04:00 PM ET)
Previous Close$59.30
Today's Range$58.05 - $59.55
52-Week Range$38.14 - $66.60
Volume501,759 shs
Average Volume337,465 shs
Market Capitalization$2.18 billion
P/E Ratio-17.70
Dividend YieldN/A
Beta1.11

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AERI
CUSIPN/A
Phone+1-919-3139650

Debt

Debt-to-Equity Ratio0.78%
Current Ratio15.24%
Quick Ratio15.24%

Price-To-Earnings

Trailing P/E Ratio-17.7014925373134
Forward P/E Ratio-15.05
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book18.77

Profitability

Trailing EPS($3.35)
Net Income$-99,050,000.00
Net MarginsN/A
Return on Equity-86.87%
Return on Assets-41.89%

Miscellaneous

Employees95
Outstanding Shares36,710,000

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) released its earnings results on Wednesday, November, 8th. The company reported ($0.89) earnings per share (EPS) for the quarter. View Aerie Pharmaceuticals' Earnings History.

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2018?

13 brokers have issued 1 year price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $48.00 to $100.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $72.46 in the next year. View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "With no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. Aerie had to withdraw its NDA in the United States submitted in 2016 as a third-party manufacturing facility in Tampa, FL, not being ready for pre-approval inspection. The delay in the NDA filing was quite disappointing as Rhopressa is Aerie’s lead late-stage candidate. Any such delays will adversely impact prospects. Aerie resubmitted its NDA for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa’s approval. A potential approval of Rhopressa will boost the company’s growth prospects. Aerie’s shares have outperformed the industry in the last six months." (11/22/2017)
  • 2. Mizuho analysts commented, "We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline." (11/9/2017)
  • 3. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
  • 4. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:

  • Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer (Age 64)
  • Thomas A. Mitro, President, Chief Operating Officer (Age 59)
  • Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer (Age 55)
  • Richard J. Rubino CPA, Chief Financial Officer, Secretary (Age 59)
  • Deanne F. Melloy, Vice President - Marketing
  • Tori Arens, Vice President - Drug Product Manufacturing
  • Eric Carlson, Vice President - Research & Development
  • Gerald D. Cagle Ph.D., Independent Director (Age 72)
  • Richard J. Croarkin, Independent Director (Age 62)
  • Michael M. Du Toit, Independent Director (Age 64)

Who owns Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $59.30.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $2.18 billion. The company earns $-99,050,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Aerie Pharmaceuticals employs 95 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 7020 Kit Creek Rd Ste 270, RESEARCH TRIANGLE PARK, NC 27709-0014, United States. The company can be reached via phone at +1-919-3139650 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (AERI)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aerie Pharmaceuticals (NASDAQ:AERI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.922.92
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $72.46$72.46$70.00$65.67
Price Target Upside: 24.29% upside24.29% upside10.58% upside19.18% upside

Aerie Pharmaceuticals (NASDAQ:AERI) Consensus Price Target History

Price Target History for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2017MizuhoReiterated RatingBuy$87.00LowView Rating Details
12/18/2017Canaccord GenuitySet Price TargetBuy$73.00HighView Rating Details
12/18/2017Cantor FitzgeraldSet Price TargetBuy$77.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$80.00N/AView Rating Details
10/16/2017Needham & Company LLCReiterated RatingBuy -> Buy$65.00 -> $76.00N/AView Rating Details
10/11/2017JMP SecuritiesSet Price TargetBuy$68.00N/AView Rating Details
10/5/2017CowenReiterated RatingBuyN/AView Rating Details
8/2/2017HC WainwrightSet Price TargetBuy$69.00HighView Rating Details
7/28/2017Stifel NicolausReiterated RatingBuy$70.00MediumView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
3/9/2017Raymond James FinancialDowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 1/21/2016 forward)

Earnings

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings History and Estimates Chart

Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.89)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.84)($0.82)ViewListenView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aerie Pharmaceuticals (NASDAQ:AERI) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.94 EPS
Next Year EPS Consensus Estimate: $-2.51 EPS

Dividends

Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.36%
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ AERI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.0010,900View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.3310,067View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.781,854View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aerie Pharmaceuticals (NASDAQ AERI) News Headlines

Source:
DateHeadline
Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and ... - Business Wire (press release)Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and ... - Business Wire (press release)
www.businesswire.com - January 18 at 3:31 PM
Aerie Pharmaceuticals Inc (AERI) Given Average Rating of "Buy" by AnalystsAerie Pharmaceuticals Inc (AERI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 16 at 3:44 PM
Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency OperationsAerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
finance.yahoo.com - January 16 at 10:12 AM
Jacobs Wins EPCM Contract for Khazzan Tight Gas ProjectJacobs Wins EPCM Contract for Khazzan Tight Gas Project
finance.yahoo.com - January 11 at 9:24 AM
Jacobs JV Unit Wins Contract for West Gate Tunnel ProjectJacobs' JV Unit Wins Contract for West Gate Tunnel Project
finance.yahoo.com - January 10 at 10:28 AM
Stock Traders Purchase High Volume of Aerie Pharmaceuticals Call Options (AERI)Stock Traders Purchase High Volume of Aerie Pharmaceuticals Call Options (AERI)
www.americanbankingnews.com - January 6 at 3:12 AM
Technical Perspectives on Drug Makers Stocks -- Aerie Pharma ... - PR Newswire (press release)Technical Perspectives on Drug Makers Stocks -- Aerie Pharma ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 3:28 PM
Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs - Business Wire (press release)
www.businesswire.com - January 2 at 9:58 AM
Amarin (AMRN) & Aerie Pharmaceuticals (AERI) Head-To-Head ContrastAmarin (AMRN) & Aerie Pharmaceuticals (AERI) Head-To-Head Contrast
www.americanbankingnews.com - December 29 at 5:28 AM
Comparing Summit Therapeutics (SMMT) and Aerie Pharmaceuticals (AERI)Comparing Summit Therapeutics (SMMT) and Aerie Pharmaceuticals (AERI)
www.americanbankingnews.com - December 27 at 1:16 PM
FDA approves Aerie drug sooner than expected – sales staff to growFDA approves Aerie drug sooner than expected – sales staff to grow
finance.yahoo.com - December 26 at 12:51 PM
Aerie Pharmaceuticals (AERI) Upgraded by BidaskClub to "Buy"Aerie Pharmaceuticals (AERI) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - December 25 at 5:10 PM
Aerie Pharmaceuticals Inc (AERI) Given Consensus Rating of "Buy" by AnalystsAerie Pharmaceuticals Inc (AERI) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 4:18 PM
Is Aerie Pharmaceuticals Inc (NASDAQ:AERI) A Financially Sound Company?Is Aerie Pharmaceuticals Inc (NASDAQ:AERI) A Financially Sound Company?
finance.yahoo.com - December 21 at 9:20 AM
Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug -- The ... - Motley FoolAerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug -- The ... - Motley Fool
www.fool.com - December 20 at 3:27 PM
Aerie Pharma (AERI) Confirms FDA Approval of Rhopressa 0.02% for Lowering of Elevated IOP in Patients with Open-Angle Glaucoma or Ocular HypertensionAerie Pharma (AERI) Confirms FDA Approval of Rhopressa 0.02% for Lowering of Elevated IOP in Patients with Open-Angle Glaucoma or Ocular Hypertension
www.streetinsider.com - December 20 at 9:20 AM
Canaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $73.00 Price TargetCanaccord Genuity Analysts Give Aerie Pharmaceuticals (AERI) a $73.00 Price Target
www.americanbankingnews.com - December 19 at 11:42 PM
Aerie Pharmaceuticals (AERI) Given a $77.00 Price Target by Cantor Fitzgerald AnalystsAerie Pharmaceuticals (AERI) Given a $77.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - December 19 at 11:42 PM
Aerie Pharmaceuticals (AERI) Earns Buy Rating from MizuhoAerie Pharmaceuticals (AERI) Earns Buy Rating from Mizuho
www.americanbankingnews.com - December 19 at 1:18 PM
Aeries glaucoma treatment gets early FDA approval - ReutersAerie's glaucoma treatment gets early FDA approval - Reuters
www.reuters.com - December 19 at 9:52 AM
Aerie Pharma eye drug Rhopressa approved by FDA - MarketWatchAerie Pharma eye drug Rhopressa approved by FDA - MarketWatch
www.marketwatch.com - December 19 at 9:52 AM
(netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle ... - Business Wire (press release)(netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle ... - Business Wire (press release)
www.businesswire.com - December 19 at 9:52 AM
Aerie (AERI) Gets Early FDA Approval for Lead Drug RhopressaAerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa
finance.yahoo.com - December 19 at 9:52 AM
Aeries glaucoma treatment gets early FDA approvalAerie's glaucoma treatment gets early FDA approval
finance.yahoo.com - December 19 at 9:52 AM
Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report?Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report?
finance.yahoo.com - December 11 at 9:43 AM
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
finance.yahoo.com - December 7 at 9:53 AM
Biotech drug pricing should not get substantially worse next year - Mizuho - Seeking AlphaBiotech drug pricing should not get substantially worse next year - Mizuho - Seeking Alpha
seekingalpha.com - December 6 at 3:28 PM
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region - Business Wire (press release)
www.businesswire.com - December 6 at 9:46 AM
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast RegionAerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
finance.yahoo.com - December 4 at 9:28 AM
Zacks: Brokerages Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$1.44 Earnings Per ShareZacks: Brokerages Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Post -$1.44 Earnings Per Share
www.americanbankingnews.com - December 3 at 3:26 PM
Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer - PR Newswire (press release)Free Research Reports on These Drug Makers Stocks -- Novartis, Heron Therapeutics, Aerie Pharma, and Pfizer - PR Newswire (press release)
www.prnewswire.com - December 1 at 12:26 PM
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources - Business Wire (press release)
www.businesswire.com - December 1 at 12:26 PM
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human ResourcesAerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
finance.yahoo.com - December 1 at 12:26 PM
Aerie Pharmaceuticals, Inc. (AERI) Given Consensus Rating of "Buy" by BrokeragesAerie Pharmaceuticals, Inc. (AERI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 4:26 PM
Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics - Business Wire (press release)Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics - Business Wire (press release)
www.businesswire.com - November 27 at 8:17 AM
Global Ophthalmic Therapeutics/Drug Market 2014-2017 & Forecasts to 2025 - Market is Expected to Reach USD 35.7 BillionGlobal Ophthalmic Therapeutics/Drug Market 2014-2017 & Forecasts to 2025 - Market is Expected to Reach USD 35.7 Billion
www.bizjournals.com - November 24 at 3:21 PM
FY2018 Earnings Estimate for Aerie Pharmaceuticals, Inc. (AERI) Issued By Cantor FitzgeraldFY2018 Earnings Estimate for Aerie Pharmaceuticals, Inc. (AERI) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 22 at 2:48 PM
Aerie Pharmaceuticals, Inc. (AERI) Stock Rating Lowered by Zacks Investment ResearchAerie Pharmaceuticals, Inc. (AERI) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 22 at 9:36 AM
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... - Business Wire (press release)Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements ... - Business Wire (press release)
www.businesswire.com - November 18 at 3:34 PM
Critical Analysis: Aerie Pharmaceuticals (AERI) versus The CompetitionCritical Analysis: Aerie Pharmaceuticals (AERI) versus The Competition
www.americanbankingnews.com - November 18 at 1:30 PM
Aerie Pharmaceuticals, Inc. (AERI) Given a $73.00 Price Target by Canaccord Genuity AnalystsAerie Pharmaceuticals, Inc. (AERI) Given a $73.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - November 18 at 12:52 PM
BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trialBRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
www.reuters.com - November 18 at 5:47 AM
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in JapanAerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
finance.yahoo.com - November 18 at 5:47 AM
Aerie Pharmaceuticals Target of Unusually Large Options Trading (AERI)Aerie Pharmaceuticals Target of Unusually Large Options Trading (AERI)
www.americanbankingnews.com - November 17 at 1:26 AM
Aerie Pharmaceuticals, Inc. (AERI) Given a $69.00 Price Target at Cantor FitzgeraldAerie Pharmaceuticals, Inc. (AERI) Given a $69.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - November 16 at 6:50 PM
 Analysts Expect Aerie Pharmaceuticals, Inc. (AERI) Will Post Earnings of -$0.67 Per Share Analysts Expect Aerie Pharmaceuticals, Inc. (AERI) Will Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 15 at 7:14 AM
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus - NasdaqAerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus - Nasdaq
www.nasdaq.com - November 9 at 4:33 PM
Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update - Business Wire (press release)Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update - Business Wire (press release)
www.businesswire.com - November 9 at 4:33 PM
Is a Surprise Coming for Aerie (AERI) This Earnings Season? - NasdaqIs a Surprise Coming for Aerie (AERI) This Earnings Season? - Nasdaq
www.nasdaq.com - November 7 at 10:12 PM
Aerie Pharmaceuticals (AERI) Buy Rating Reaffirmed at MizuhoAerie Pharmaceuticals' (AERI) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - November 4 at 10:52 PM

SEC Filings

Aerie Pharmaceuticals (NASDAQ:AERI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aerie Pharmaceuticals (NASDAQ:AERI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aerie Pharmaceuticals (NASDAQ AERI) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.